featured
Nivolumab, Nivolumab–Ipilimumab, and VEGFR-TKIs as First-Line Treatment for Metastatic ccRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
Lancet Oncol 2022 Apr 04;[EPub Ahead of Print], YA Vano, R Elaidi, M Bennamoun, C Chevreau, D Borchiellini, D Pannier, D Maillet, M Gross-Goupil, C Tournigand, B Laguerre, P Barthélémy, E Coquan, G Gravis, N Houede, M Cancel, O Huillard, P Beuzeboc, L Fournier, A Méjean, X Cathelineau, N Doumerc, P Paparel, JC Bernhard, A de la Taille, K Bensalah, T Tricard, T Waeckel, G Pignot, E Braychenko, S Caruso, CM Sun, V Verkarre, G Lacroix, M Moreira, M Meylan, A Bougouïn, L Phan, C Thibault-Carpentier, J Zucman-Rossi, WH Fridman, C Sautès-Fridman, S OudardFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.